Inclusion Criteria:

- Cytologically or histologically confirmed diagnosis of Stage IV NSCLC as defined by
the American Joint Committee on Cancer Staging Criteria for Lung Cancer (AJCC 7th
edition 2009).

- Eligible for first-line treatment with erlotinib based on documented evidence of
tumor harboring an activating EGFR mutation (Example 19 del and L858R).

- Mandatory provision of adequate archived stage IV NSCLC tissue sample.

- At least one measurable lesion.

- Life expectancy of at least 3 months.

Exclusion Criteria:

- Known T790M EGFR mutation.

- Known leptomeningeal carcinomatosis, uncontrolled/unstable spinal cord compression,
or brain metastases.

- Serious illness or medical condition.

- Ongoing treatment with CYP3A4 inducers or strong/moderate inhibitors.

- Ongoing therapy with nonsteroidal anti-inflammatory drugs for more than 2 months.

- History of gross hemoptysis.

- Significant bleeding disorders.

- Radiologically documented evidence of major blood vessel invasion or encasement by
cancer.

- Radiographic evidence of intratumor cavitation.

- History of gastrointestinal perforation within last 6 months.

- History of bowel obstruction, inflammatory enteropathy or extensive intestinal
resection.

- History of any arterial thrombotic event within 6 months prior to enrollment.

- The participant has any known significant ophthalmologic abnormalities of the surface
of the eye.

Minimum Eligible Age: 18 Years

Maximum Eligible Age: N/A

Eligible Gender: Both